A Phase 2 interventional study of Ritivixibat in Primary Sclerosing Cholangitis, sponsored by Albireo, an Ipsen Company. Terminated at 8 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by Albireo, an Ipsen Company (part of Ipsen) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Cholangitis, Sclerosing with a site in Italy — 5 open to participants now, 8 under way, 2 of them phase 3. Cholangitis, Sclerosing · Italy.
Among the 14 studies in Cholangitis, Sclerosing with a site in Italy, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 2, and was the 8th registered.
152 studies on the registry are indexed under Cholangitis, Sclerosing; 42 are open to participants now.
Browse Cholangitis, Sclerosing studies →5 of the 14 studies in Cholangitis, Sclerosing with a site in Italy are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in Italy, Belgium, France and 2 more countries
Ages 18–70
Ipsen · Sites in Italy, United States, Argentina and 22 more countries
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in Italy, Austria, Belgium and 4 more countries
Ages 18–70
University of Milano Bicocca · Sites in Italy
Ages 15–70
University of Milano Bicocca · Sites in Italy
Ages 17+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 33 across 96 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 87 across the 10 interventional studies, 2,565 across the 4 observational. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
This study is registered under Albireo, an Ipsen Company, one of the names counted as Ipsen. Under that name alone:
Albireo, an Ipsen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.
Ipsen has 3 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Cholangitis, Sclerosing with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC).
This study will test a drug called A3907 to see how safe and tolerated it is for treating people with Primary Sclerosing Cholangitis (PSC). Detailed Description: The primary goal of this study in participants with PSC with and without a Clinically Relevant Stricture (CRS) who are treated with A3907 is to assess the safety and tolerability of A3907 following repeat doses. Secondary goals include evaluation of the pharmacokinetic properties of A3907 (the study of how the body interacts with A3907 for the entire duration of exposure) and changes in safety parameters via laboratory testing such as liver enzymes, bile acid levels and markers of bile acid synthesis
Key inclusion criteria:
Key exclusion criteria:
Liver cirrhosis as assessed by any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg tablet A3907 administered orally once daily for 12 weeks.
Drug: Ritivixibat
30mg (3x10 mg tablets) A3907 administered orally once daily for 12 weeks.
Drug: Ritivixibat
30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.
Drug: Ritivixibat
30mg (3x10 mg tablets) A3907 administered orally Bi-daily for 12 weeks.
Drug: Ritivixibat
10mg tablet A3907 administered orally
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An adverse event (AE) was any untoward medical occurrence in an enrolled participant regardless of causal relationship with study drug. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or an important medical event. A TEAE was any AE or worsening of an existing disease that occurred after the first dose of study drug and within the 14-day follow-up.
Time frame: From first dose of study drug (Day 1) up to 14 days post last dose, approximately 112 days
Maximum Observed Plasma Concentration (Cmax) of A3907
Blood samples were collected at specified timepoints to assess Cmax of A3907. The pharmacokinetic (PK) analysis was conducted after single dose (Day 0) and repeated dose administration (Day 98).
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10 hours post-dose on Days 0 and 98
Area Under the Plasma Concentration-time Curve From Time Zero to Time t (Time of Last Quantifiable Plasma Concentration) (AUC0-t) of A3907
Blood samples were collected at specified timepoints to assess AUC0-t of A3907.
Time frame: Pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10 hours post-dose on Days 0 and 98
Change From Baseline to Week 12 in Serum and Urine Individual and Total Bile Acid Levels
Blood and urine samples were collected at specified timepoints to assess serum and urine individual and total bile acid levels. Baseline=average of all screening results and results on day of planned single dose if both results were available. Otherwise, baseline=last non-missing assessment prior to study drug administration of planned single dose. CA=Cholic Acid; LCA=lithocholic acid; DCA=deoxycholic acid; CDCA=chenodeoxycholic acid; UDCA= ursodeoxycholic acid; GCA=glycocholic acid; GLCA=glycolithocholic acid; GDCA=glycodeoxycholic acid; GCDCA=glycochenodeoxycholic acid; GUDCA= glycoursodeoxycholic acid; TCA=taurocholic acid; TCDCA=taurochenodeoxycholic acid; TDCA=taurodeoxycholic acid; TLCA=taurolithocholic acid; TUDCA=tauroursodeoxycholic acid; S=sulfate. Calculated total bile acids without all UDCA bile acids is the sum of all individual bile acids excluding all UDCAs (UDCA, GUDCA, TUDCA). Conjugated bile acids include GCA, GLCA, GDCA, GCDCA, GUDCA, TCA, TCDCA, TDCA, TLCA, TUDCA.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline to Week 12 in Liver Biochemical Tests (LBTs): Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT) and Alkaline Phosphatase (ALP)
Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline to Week 12 in Liver Biochemical Tests: Total and Direct Bilirubin Levels
Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4)
Blood samples were collected at specified timepoints to assess C4. Baseline was defined as the assessment performed on the day of the planned single dose.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF-19)
Blood samples were collected at specified timepoints to assess FGF-19. Baseline was defined as the assessment performed on the day of the planned single dose.
Time frame: Baseline (Day 1) and Week 12
This Phase II, open-label study was conducted at 8 investigational sites in 4 countries in adults with primary sclerosing cholangitis (PSC). A total of 18 participants were enrolled in the study.
| Milestone | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Started | 8 | 6 | 4 |
| Completed | 6 | 3 | 1 |
| Not completed | 2 | 3 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Withdrew: Exposure level exceeded safety margins | 2 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 | 2 |
An adverse event (AE) was any untoward medical occurrence in an enrolled participant regardless of causal relationship with study drug. An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or an important medical event. A TEAE was any AE or worsening of an existing disease that occurred after the first dose of study drug and within the 14-day follow-up.
| Participants | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| TEAEs | 5 | 6 | 3 |
| TESAEs | 0 | 1 | 0 |
Blood samples were collected at specified timepoints to assess Cmax of A3907. The pharmacokinetic (PK) analysis was conducted after single dose (Day 0) and repeated dose administration (Day 98).
| nanogram/milliliter (ng/mL) | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Day 0 | 47.1 ± 67.9 | 142 ± 53.7 | 78.3 ± 240.2 |
| Day 98 | 35.9 ± 71.9 | 134 ± 22.4 | NA ± NA |
Blood samples were collected at specified timepoints to assess AUC0-t of A3907.
| hour*ng/mL | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Day 0 | 309 ± 76.4 | 866 ± 58.0 | 604 ± 189.4 |
| Day 98 | 223 ± 61.1 | 936 ± 9.3 | NA ± NA |
Blood and urine samples were collected at specified timepoints to assess serum and urine individual and total bile acid levels. Baseline=average of all screening results and results on day of planned single dose if both results were available. Otherwise, baseline=last non-missing assessment prior to study drug administration of planned single dose. CA=Cholic Acid; LCA=lithocholic acid; DCA=deoxycholic acid; CDCA=chenodeoxycholic acid; UDCA= ursodeoxycholic acid; GCA=glycocholic acid; GLCA=glycolithocholic acid; GDCA=glycodeoxycholic acid; GCDCA=glycochenodeoxycholic acid; GUDCA= glycoursodeoxycholic acid; TCA=taurocholic acid; TCDCA=taurochenodeoxycholic acid; TDCA=taurodeoxycholic acid; TLCA=taurolithocholic acid; TUDCA=tauroursodeoxycholic acid; S=sulfate. Calculated total bile acids without all UDCA bile acids is the sum of all individual bile acids excluding all UDCAs (UDCA, GUDCA, TUDCA). Conjugated bile acids include GCA, GLCA, GDCA, GCDCA, GUDCA, TCA, TCDCA, TDCA, TLCA, TUDCA.
| micromole/liter (umol/L) | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Serum CA | 0.4885 ± 0.9331 | -0.1753 ± 0.5502 | 0.0560 ± 0.0550 |
| Serum LCA | 0.0151 ± 0.0484 | 0.0261 ± 0.0655 | -0.0104 ± 0.0146 |
| Serum DCA | 0.2717 ± 0.4695 | 0.2679 ± 0.3591 | -0.0456 ± 0.0528 |
| Serum CDCA | 0.8167 ± 1.1989 | 0.0039 ± 0.1233 | 0.1613 ± 0.2870 |
| Serum UDCA | 4.6122 ± 6.0338 | -3.5851 ± 5.7702 | -1.1110 ± 1.4305 |
| Serum GCA | 1.3351 ± 2.3384 | -1.8013 ± 5.2396 | 0.3603 ± 0.0326 |
| Serum GLCA | 0.0175 ± 0.1967 | 0.0325 ± 0.3491 | -0.0212 ± 0.0300 |
| Serum GDCA | 2.1247 ± 2.8012 | 5.5493 ± 13.3255 | -0.3383 ± 0.8731 |
| Serum GCDCA | 5.0845 ± 7.6696 | 2.4643 ± 13.6973 | 4.2567 ± 6.7475 |
| Serum GUDCA | 11.5201 ± 14.0272 | 4.2602 ± 28.0844 | -4.6380 ± 1.2898 |
| Serum TCA | 0.2912 ± 0.7627 | -3.0008 ± 4.1924 | -0.7998 ± 1.5993 |
| Serum TCDCA | 0.4840 ± 0.9149 | -1.3761 ± 3.6052 | 0.1130 ± 0.3271 |
| Serum TDCA | 0.1295 ± 0.2088 | -0.1607 ± 1.4477 | -0.1464 ± 0.3922 |
| Serum TLCA | -0.0002 ± 0.0385 | -0.0508 ± 0.1124 | -0.0054 ± 0.0077 |
| Serum TUDCA | 0.9627 ± 1.5129 | -1.8607 ± 4.4925 | -1.2759 ± 0.1619 |
| Serum total bile acids-KI | 28.1533 ± 36.3683 | 0.5934 ± 65.2963 | -3.4447 ± 6.4230 |
| Serum total bile acids-GCL | 32.7500 ± 48.0778 | 8.3750 ± 86.8028 | 0.6667 ± 4.2426 |
| Serum total bile acids (calculated) without all UDCAs bile acid | 11.0582 ± 16.8346 | 1.7790 ± 38.0268 | 3.5803 ± 3.8647 |
| Conjugated serum bile acids | 21.9490 ± 29.8683 | 4.0558 ± 69.7236 | -2.4951 ± 4.6887 |
| Unconjugated serum bile acids | 6.2043 ± 8.1301 | -3.4624 ± 6.1819 | -0.9497 ± 1.7343 |
| Urine CA | 0.4831 ± 0.3881 | 0.0657 ± 0.0842 | 0.1562 |
| Urine LCA | 0.0088 ± 0.0140 | 0.0049 ± 0.0104 | 0.0000 |
| Urine DCA | 0.0248 ± 0.0298 | 0.0254 ± 0.0348 | 0.0000 |
| Urine CDCA | 0.0103 ± 0.0087 | 0.0020 ± 0.0087 | 0.0000 |
| Urine UDCA | 0.1338 ± 0.1513 | 0.0935 ± 0.2295 | 0.0183 |
| Urine GCA | 0.4344 ± 0.6883 | -0.6828 ± 1.8381 | 0.2483 |
| Urine GLCA | 0.0058 ± 0.0091 | -0.0001 ± 0.0002 | 0.0000 |
| Urine GDCA | 0.1260 ± 0.1397 | 0.0191 ± 0.4760 | -0.0102 |
| Urine GCDCA | 0.0606 ± 0.0939 | -0.0682 ± 0.2017 | 0.0162 |
| Urine GUDCA | 17.6985 ± 24.4586 | -2.6098 ± 22.9701 | 0.6844 |
| Urine CA-S | -0.0656 ± 0.1611 | -0.0072 ± 0.0076 | 0.0041 |
| Urine LCA-S | 0.0933 ± 0.0903 | 0.2142 ± 0.4239 | 0.0000 |
| Urine DCA-S | 0.0954 ± 0.2697 | 0.0327 ± 0.0915 | -0.0315 |
| Urine CDCA-S | -0.0176 ± 0.1047 | 0.1086 ± 0.2254 | -0.0116 |
| Urine UDCA-S | -0.7360 ± 5.5327 | 1.1988 ± 3.4228 | 0.0616 |
| Urine GCA-S | -0.1996 ± 0.9580 | -2.1408 ± 3.5941 | -0.0137 |
| Urine GLCA-S | -2.2804 ± 21.4492 | -11.3853 ± 13.7351 | -0.0568 |
| Urine GDCA-S | 6.3690 ± 16.0747 | -10.6307 ± 25.1248 | -1.0202 |
| Urine GCDCA-S | 1.4066 ± 4.4791 | -3.9908 ± 7.1694 | -0.0223 |
| Urine GUDCA-S | -1.6910 ± 126.5646 | 14.1540 ± 37.1691 | -2.1189 |
| Urine total bile acids | 21.9601 ± 179.9461 | -15.5970 ± 71.0133 | -2.0963 |
| Urine total bile acids (calculated) without all UDCAs bile acid | 6.5548 ± 39.9565 | -28.4334 ± 51.0251 | -0.7417 |
| Conjugated urine bile acids | 18.3253 ± 25.3490 | -3.3419 ± 25.4237 | 0.9387 |
| Unconjugated urine bile acids | 0.6608 ± 0.5074 | 0.1914 ± 0.3603 | 0.1745 |
| Conjugated urine sulfated bile acids | 3.6045 ± 157.4674 | -13.9937 ± 47.9874 | -3.2320 |
| Unconjugated urine sulfated bile acids | -0.6305 ± 5.8407 | 1.5471 ± 3.8482 | 0.0225 |
Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.
| Units/liter | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| ALT | 1.500 ± 37.3698 | -14.500 ± 47.0815 | 0.333 ± 41.0122 |
| AST | 0.833 ± 33.4644 | -13.000 ± 25.8618 | -7.167 ± 22.3917 |
| GGT | 50.500 ± 49.8849 | -39.500 ± 132.6292 | 68.500 ± 37.9481 |
| ALP | 55.417 ± 78.7359 | -16.375 ± 53.3547 | 22.667 ± 61.2826 |
Blood samples were collected at specified timepoints to assess LBTs. Baseline was defined as the average of all screening results and results on the day of the planned single dose if both results were available. Otherwise, baseline was defined as the last non-missing assessment prior to the study drug administration of planned single dose.
| umol/L | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Total bilirubin | -0.700 ± 2.6414 | -3.988 ± 4.1003 | -2.117 ± 0.3064 |
| Direct bilirubin | 0.425 ± 1.7745 | -1.600 ± 2.8534 | -0.283 ± 0.1179 |
Blood samples were collected at specified timepoints to assess C4. Baseline was defined as the assessment performed on the day of the planned single dose.
| microgram/liter | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Change From Baseline to Week 12 in 7α-hydroxy-4-cholesten-3-one (C4) | -2.333 ± 11.8162 | -3.860 ± 18.2600 | 17.233 ± 27.8011 |
Blood samples were collected at specified timepoints to assess FGF-19. Baseline was defined as the assessment performed on the day of the planned single dose.
| ng/L | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| Change From Baseline to Week 12 in Fibroblast Growth Factor 19 (FGF-19) | -23.7 ± 31.56 | -129.3 ± 190.72 | -6.5 ± 21.92 |
Collected over Adverse events were collected from first dose of study drug (Day 1) up to 14 days post last dose, approximately 112 days. Deaths (all-cause mortality) were collected from first dose of study drug (Day 1) up to end of follow-up per participant, maximum of 30 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A3907 10 mg QD | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| A3907 30 mg QD | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| A3907 30 mg BID With CRS | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| CholangitisHepatobiliary disorders | 0/8 | 1/6 | 0/4 |
| Event | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/8 | 3/6 | 2/4 |
| Crystal urine presentInvestigations | 0/8 | 0/6 | 2/4 |
| Abdominal painGastrointestinal disorders | 1/8 | 2/6 | 1/4 |
| FlatulenceGastrointestinal disorders | 0/8 | 1/6 | 1/4 |
| Alanine aminotransferase increasedInvestigations | 1/8 | 1/6 | 1/4 |
| Aspartate aminotransferase increasedInvestigations | 1/8 | 1/6 | 1/4 |
| Blood urine presentInvestigations | 0/8 | 0/6 | 1/4 |
| White blood cells urine positiveInvestigations | 0/8 | 0/6 | 1/4 |
| AstheniaGeneral disorders | 2/8 | 1/6 | 0/4 |
| PyrexiaGeneral disorders | 0/8 | 1/6 | 1/4 |
The safety analysis set included all participants who received at least 1 dose of A3907.
| Age, Continuous(years) | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS | Total |
|---|---|---|---|---|
| Mean | 42.3 ± 9.82 | 43.0 ± 11.08 | 37.8 ± 14.57 | 41.5 ± 10.85 |
| Sex: Female, Male(Participants) | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 0 | 1 |
| Male | 8 | 5 | 4 | 17 |
| Ethnicity (NIH/OMB)(Participants) | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 7 | 5 | 4 | 16 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | A3907 10 mg QD | A3907 30 mg QD | A3907 30 mg BID With CRS | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 8 | 6 | 4 | 18 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.
Access criteria: Access Criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).
Data sharing details ↗ · vivli.org
Ran from Jan 2023 to primary completion in Jul 2025, 30 months.
Results were first posted in May 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.